.Attributes Medication, Posted online: 30 July 2024 doi:10.1038/ d41591-024-00054-wThe antibody-- medication conjugate (ADC) tisotumab vedotin caused boosted progression-free as well as general survival, bring about FDA commendation and also a brand new treatment possibility for patients.